Cargando…

Comparison of Lipid-Lowering Effects of Anagliptin and Miglitol in Patients With Type 2 Diabetes: A Randomized Trial

BACKGROUND: Recently, we reported that the level of lathosterol, a cholesterol synthesis marker, was suppressed after 1 month of treatment with anagliptin, a dipeptidyl peptidase-4 inhibitor. In this study, we administered either anagliptin or miglitol, an alpha-glucosidase inhibitor, for 3 months i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iijima, Takahiro, Aoki, Kazutaka, Kondo, Yoshinobu, Terauchi, Yasuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011936/ https://www.ncbi.nlm.nih.gov/pubmed/32095176 http://dx.doi.org/10.14740/jocmr4084

Ejemplares similares

Additive Effects of Miglitol and Anagliptin on Insulin-Treated Type 2 Diabetes Mellitus: A Case Study
por: Kishimoto, Miyako, et al.
Publicado: (2014)

Effect of Anagliptin on Glycemic and Lipid Profile in Patients With Type 2 Diabetes Mellitus
por: Chiba, Yukari, et al.
Publicado: (2018)

Effects of miglitol taken just before or after breakfast on plasma glucose, serum insulin, glucagon and incretin levels after lunch in men with normal glucose tolerance, impaired fasting glucose or impaired glucose tolerance
por: Masuda, Kiyomi, et al.
Publicado: (2011)

Comparison of the Effectiveness of Once-Daily Alogliptin/Metformin and Twice-Daily Anagliptin/Metformin Combination Tablet in a Randomized, Parallel-Group, Open-Label Trial in Japanese Patients with Type 2 Diabetes
por: Yamazaki, Shunsuke, et al.
Publicado: (2022)

Comparison of effects of anagliptin and alogliptin on serum lipid profile in type 2 diabetes mellitus patients
por: Kurozumi, Akira, et al.
Publicado: (2017)

Incretin Kinetics Before and After Miglitol in Japanese Patients With Late Dumping Syndrome
por: Amagai, Mari, et al.
Publicado: (2017)

A Randomized Controlled Trial of a Mini Low-Carbohydrate Diet and an Energy-Controlled Diet Among Japanese Patients With Type 2 Diabetes
por: Kimura, Masayo, et al.
Publicado: (2018)

Correction to: A Randomized Controlled Trial of a Mini Low-Carbohydrate Diet and an Energy-Controlled Diet Among Japanese Patients With Type 2 Diabetes
por: Kimura, Masayo, et al.
Publicado: (2018)

Comparison of Azelnidipine and Trichlormethiazide in Japanese Type 2 Diabetic Patients with Hypertension: The COAT Randomized Controlled Trial
por: Takihata, Masahiro, et al.
Publicado: (2015)

Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial
por: Iijima, Takahiro, et al.
Publicado: (2023)

Effect of the Addition of Sitagliptin and Miglitol on Insulin-Treated Type 2 Diabetes
por: Kishimoto, Miyako, et al.
Publicado: (2012)

Combination therapy of miglitol and insulin in type 1 diabetes mellitus patients
por: Kubo, Sayaka, et al.
Publicado: (2010)

Comparison of the effects of empagliflozin and glimepiride on endothelial function in patients with type 2 diabetes: A randomized controlled study
por: Tamura, Haruka, et al.
Publicado: (2022)

Mechanism of lipid‐lowering action of the dipeptidyl peptidase‐4 inhibitor, anagliptin, in low‐density lipoprotein receptor‐deficient mice
por: Yano, Wataru, et al.
Publicado: (2016)

Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability
por: Nishio, Shinya, et al.
Publicado: (2015)

Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial
por: Chihara, Atsuko, et al.
Publicado: (2019)

Dissimilar Effects of Anagliptin and Sitagliptin on Lipoprotein Subclass in Standard or Strong Statin-Treated Patients with Type-2 Diabetes Mellitus: A Subanalysis of the REASON (Randomized Evaluation of Anagliptin versus Sitagliptin on Low-Density LipoproteiN Cholesterol in Diabetes) Trial
por: Hirai, Hiroyuki, et al.
Publicado: (2019)

Effects of liraglutide and empagliflozin added to insulin therapy in patients with type 2 diabetes: A randomized controlled study
por: Nakaguchi, Hirotatsu, et al.
Publicado: (2020)

Comparison of Plasma Glucose and Gut Hormone Levels Between Drinking Enteral Formula Over a Period of 5 and 20 Minutes in Japanese Patients With Type 2 Diabetes: A Pilot Study
por: Kamiko, Kazunari, et al.
Publicado: (2016)

Effects of miglitol in platelet-derived microparticle, adiponectin, and selectin level in patients with type 2 diabetes mellitus
por: Nomura, Shosaku, et al.
Publicado: (2011)

The Effects of Bazedoxifene on Bone, Glucose, and Lipid Metabolism in Postmenopausal Women With Type 2 Diabetes: An Exploratory Pilot Study
por: Yoshii, Taishi, et al.
Publicado: (2015)

Evaluation of the efficacy and tolerability of miglitol in Chinese patients with type 2 diabetes mellitus inadequately controlled by diet and sulfonylureas
por: Hsieh, Sheng-Hwu, et al.
Publicado: (2010)

The Effects of Ramelteon on Glucose Metabolism and Sleep Quality in Type 2 Diabetic Patients With Insomnia: A Pilot Prospective Randomized Controlled Trial
por: Tsunoda, Tetsuji, et al.
Publicado: (2016)

TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development Mediated by Anagliptin in Diabetic Rats
por: Kaya, Daisuke, et al.
Publicado: (2019)

Effects of Miglitol, Acarbose, and Sitagliptin on Plasma Insulin and Gut Peptides in Type 2 Diabetes Mellitus: A Crossover Study
por: Ueno, Hiroaki, et al.
Publicado: (2015)

Dipeptidyl peptidase‐4 inhibitor, anagliptin, alters hepatic insulin clearance in relation to the glycemic status in Japanese individuals with type 2 diabetes
por: Abe, Takahiro, et al.
Publicado: (2021)

Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner
por: Kitada, Munehiro, et al.
Publicado: (2017)

Dipeptidyl peptidase-4 inhibitor anagliptin reduces fasting apolipoprotein B-48 levels in patients with type 2 diabetes: A randomized controlled trial
por: Onoue, Takeshi, et al.
Publicado: (2020)

Stability-Indicating RP-HPLC Method for Estimation of Miglitol in Bulk and Tablets
por: Shrivastava, B., et al.
Publicado: (2010)

Review: Miglitol has potential as a therapeutic drug against obesity
por: Sugimoto, Satoru, et al.
Publicado: (2015)

Association between ANGPTL3, 4, and 8 and lipid and glucose metabolism markers in patients with diabetes
por: Harada, Marina, et al.
Publicado: (2021)

Effect of Caloric Intake 25 or 30 kcal/kg/day on the Glycemic Control in Obese Patients With Type 2 Diabetes
por: Masuda, Kiyomi, et al.
Publicado: (2013)

Miglitol improves postprandial endothelial dysfunction in patients with acute coronary syndrome and new-onset postprandial hyperglycemia
por: Kitano, Daisuke, et al.
Publicado: (2013)

Defining criteria for the introduction of liraglutide using the glucagon stimulation test in patients with type 2 diabetes
por: Kondo, Yoshinobu, et al.
Publicado: (2013)

Correction: Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner
Publicado: (2017)

Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial
por: Teragawa, Hiroki, et al.
Publicado: (2022)

Effects of Tofogliflozin and Anagliptin Alone or in Combination on Glucose Metabolism and Atherosclerosis-Related Markers in Patients with Type 2 Diabetes Mellitus
por: Nomura, Shosaku, et al.
Publicado: (2023)

Effect of Sitagliptin on Lipid Profile in Patients With Type 2 Diabetes Mellitus
por: Shigematsu, Erina, et al.
Publicado: (2014)

A pilot study of the efficacy of miglitol and sitagliptin for type 2diabetes with a continuous glucose monitoring system and incretin-related markers
por: Kishimoto, Miyako, et al.
Publicado: (2011)

Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial
por: Morimoto, Takeshi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1fdpqfod8u05n9cki194qkcos6